CD274 and non-small cell lung carcinoma: Data from patients with advanced NSCLC in a phase III study (KEYNOTE-024) demonstrated an objective response rate (ORR) with pembrolizumab in 44.8% of patients with at least 50% PD-L1-positive TCs compared with the ORR of 27.8% with chemotherapy.